Basal Insulin Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

MARKET INTRODUCTION

Diabetes is a type of a metabolic disorder characterized by a high blood sugar level over a prolonged period. Symptoms often include frequent urination, increased thirst, and increased appetite.The main job of basal insulin is to keep one's blood glucose levels stable during periods of fasting, like while sleeping. During fasting, the liver continuously secretes glucose into the bloodstream. Basal insulin helps maintain these glucose levels. Without basal insulin, glucose levels would rise at an alarming rate. It ensures that one's cells are fed with a constant glucose stream to burn for energy throughout the day.

MARKET DYNAMICS

The basal insulinmarket has shown a significant evolution over the forecast period.The rise of the basal insulin market is driven by therising prevalence of diabetes, the growing geriatric population, technological advancements in insulin delivery devices, and increasing population exposure to risk factors leading to diabetes.Approximately 100 million individuals worldwide need insulin, including all individuals living with type 1 diabetes and 10-25% of individuals with type 2 diabetes. Basal insulin is the most widely used insulin in diabetic patients owing to its long-acting effect. However, although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today are still unable to afford and access it, which is likely to restrict the market's growth. Conversely, product launches are boosting the market's growth. For instance, Tresiba, launched by Novo Nordisk in 2016, received encouraging feedback from the patients and is expected to show tremendous growth during the forecast period (2021-2024) due to its ultra-long-acting effect.

MARKET SCOPE

The "Basal InsulinMarket Analysis to 2031" is a specialized and in-depth study of thehealthcare industry's pharmaceuticals,focusing on the global market trend analysis. This report outlines the basal insulinmarket with detailed market segmentation bytype, application, and end-user. The basal insulinmarket isestimated to witness a high rise during the forecast period. It focuses on the vital statistics on leading players' market status in the basal insulin market and provides key opportunities and trends.

MARKET SEGMENTATION

The market is categorized based onthetype, application, and end user. Based on thetype, the market is segmented aslantus, levemir, toujeo, and others. Based on the application,the segmentationof the market is into type I diabetes, type II diabetes, gestational diabetes, and prediabetes. Basedon end user,the segmentation of the market is intohospitals,clinics,and others.

REGIONAL FRAMEWORK

The report states a detailed outline of the industry, consisting of both quantitative and qualitative information. It offers a sketch and forecast of the basal insulinmarket based onvarious segments.The report also consists ofmarket size and forecast estimates from the year 2021 to2031with respect to five main regions, namely; North America,Asia-Pacific (APAC), Europe,Middle East, and Africa (MEA), and South & Central America (SCAM). The basal insulinmarket by each region is then sub-segmented into respective countries and segments. It comprises the analysis and forecast of 18 countriesglobally and the recent trend and opportunities prevailing in the region.

The report analyzes factors affecting the basal insulinmarket from both the demand and supply sides. Furthermore, it evaluates market dynamics regarding the market during the forecast period, i.e., drivers, restraints, opportunities, and future trends. It also consists of precise PEST analysis for all five regions, namely, North America, Asia Pacific,Europe, Middle East, and Africa, and South & Central America, after assessing political, social, economic,and technological factors affecting the basal insulinmarket in these regions.

MARKET PLAYERS

The report contains critical developments in the basal insulinmarket as inorganic and organic growth strategies. Several companies are pivoting on organic growth strategies like product launches, product approvals, and others, such aspatentsand events. Inorganic growth strategies observed were collaborations and acquisitions &partnerships. Various such activities have paved the path for elaboratingthe business and customer base of market players. The market players from the basal insulinmarket are estimated to have profitable growth opportunities in the coming years with the higher demand for basal insulinin the global market. Given below is the list of a few companies engaged in the basal insulinmarket.
The report also offers key players' profiles in the basal insulin market and their SWOT analysis and market strategies.The report also focuses on the key market players with information on company profiles, financial information of the last three years, components, and services provided,critical development in the past five years.

•  Novo Nordisk
  
•  Sanofi
  
•  Eli Lilly and Company.
  
•  Biocon.
  
•  Julphar
  
•  BoehringerIngelheim.
  
•  Teva Pharmaceutical Industries Ltd.
  
•  Bristol-Myers Squibb Company
  
•  Pfizer
  
•  GlaxoSmithKline plc.
  

The Insight Partner's dedicated research and the analytical team comprises of experienced professionals with advanced statistical expertise and offersseveral customization options in the current report.

Basal Insulin Report Scope